////////////National award, contribution to Pharma society, Times Network, Excellence in HEALTHCARE, 5th July, 2018, Taj Lands End, Mumbai, India, ANTHONY CRASTO
#hotpersoninawheelchair
#worlddrugtracker
////////////National award, contribution to Pharma society, Times Network, Excellence in HEALTHCARE, 5th July, 2018, Taj Lands End, Mumbai, India, ANTHONY CRASTO
#hotpersoninawheelchair
#worlddrugtracker
Pidotimod
H-Pyr-Thz-OH
(4R)-3-[(2S)-5-oxopyrrolidine-2-carbonyl]-1,3-thiazolidine-4-carboxylic acid
CAS 121808-62-6
Thymodolic acid, Pidotimod, Timodolic acid, PGT/1A, Axil, Onaka, Pigitil, Polimod
(4R)-3-(5-oxo-L-prolyl)-l ,3-thiazolidine-4-carboxylic acid, ITI 231723.
3-(L-pyroglutamyl)-L-thiazolidine-4-carboxylic acid
| Pidotimod; 121808-62-6; (R)-3-((S)-5-Oxopyrrolidine-2-carbonyl)thiazolidine-4-carboxylic acid; Pidotomod; PGT/1A; Pidotimod [INN]; | |
| Molecular Formula: | C9H12N2O4S |
|---|---|
| Molecular Weight: | 244.26758 g/mol |
Stefano Poli, Corona Lucio Del
Pidotimod is an immunostimulant.[1]
Pidotimod, whose chemical name is (4R)-3-(5-oxo-L-prolyl)-l ,3-thiazolidine-4-carboxylic acid, was first disclosed in ITI 231723. It is a synthetic peptide-like molecule provided with an in vitro and in vivo immunomodulating action (Giagulli et al., International Immunopharmacology, 9, 2009, 1366-1373). The immune system assists in maintaining a homeostatic balance between the human body and all foreign substances. An abnormality in this balance may cause a defective or aberrant response towards non-self substances…
View original post 1,896 more words
4,4,5,5-tetramethyl-2-phenethyl-1,3,2-dioxaborolanehttp://orgsyn.org/demo.aspx?prep=v94p0234 4,4,5,5-Tetramethyl-2-phenethyl-1,3,2-dioxaborolane (1) has the following physical and spectroscopic properties: Rf = 0.47 (3:97, ethyl acetate:pentane), the checkers report the following values for 1: Rf = 0.09 (3:97 ethyl acetate:pentane); Rf = 0.52 (10% EtOAc in hexanes); Merck silica gel 60 F254 plate; mp 38-39 °C; 1H NMR pdf(CDCl3, 400 MHz) δ: 1.18 (t, J = 8.4 Hz, 2H), 1.26 (s, 12H), 2.79 (t, J = 8.0 Hz, 2H), 7.16-7.22 (m,…
via 4,4,5,5-Tetramethyl-2-phenethyl-1,3,2-dioxaborolane — ORGANIC SPECTROSCOPY INTERNATIONAL
3,5-Dichloro-4-morpholinopyridine
Preparation of 4-(3,5-Dichloropyridin-4-yl)morpholine (5).(Pichowicz, M.; Crumpler, S.; McDonald, E.; Blagg, J. Tetrahedron 2010, 66, 2398, DOI: 10.1016/j.tet.2010.01.101)
/////////////
Clc2cncc(Cl)c2N1CCOCC1
C23H2F2N5O5PS▪C6H14N2O2▪C2H6O : 739.73
[914361-45-8]
[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1,2,4-triazol-1-yl)butan-2-yl]oxymethyl dihydrogen phosphate;(2S)-2,6-diaminohexanoic acid;ethanol
L-Lysine [[(2R,3R)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-yl]oxy]methyl dihydrogen phosphate ethanol
BFE-1224
BMS-379224
E-1224
ravuconazole prodrugs, ravuconazole methyl phosphate
fosravuconazole bis(L-lysine)
ホスラブコナゾール L－リシンエタノール付加物
| Formula | C23H20F2N5O5PS. C6H14N2O2. C2H6O |
|---|---|
| CAS | 914361-45-8 |
| Mol weight | 739.727 |
Antifungal, Ergosterol biosynthesis inhibitor
Fungal infection; Onychomycosis; Trypanosoma cruzi infection
PMDA JAPAN APPROVED
| 2018/1/19 | PMDA | APPROVED | Fosravuconazole L-lysine ethanolate | Nailin | Sato Pharmaceutical
FOR Tinea, nail (onychomycosis) |
NOTE THIS STR
Drugs for Neglected Diseases initiative (DNDi), under license from Eisai, is developing fosravuconazole for CD and eumycetoma
In February 2013, the drug was in phase II/III development by Seren Pharmaceuticals for onychomycosis in North America, Europe and Asia, including Japan,
In 2010, the product was licensed exclusively to Brain Factory (now Seren Pharma) for development, commercialization and sublicense in Japan for the…
View original post 719 more words
